A Phase I, Blinded Within Dose Groups, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Titration Schemes of BI 456906 in Patients With Obesity and Overweight.
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
At a glance
- Drugs BI 456906 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 04 Feb 2019 Planned End Date changed from 11 Mar 2019 to 18 Oct 2019.
- 04 Feb 2019 Planned primary completion date changed from 21 Feb 2019 to 13 Sep 2019.
- 23 Aug 2018 Status changed from not yet recruiting to recruiting.